Bio-Branding is a brand new Bioassociate service for biotech and life science start-ups looking for optimize their online presence and “investability”. Read about our new service here.

As an introduction, check out our latest Pharmaphorum article, “Bio-Brand your way through the valley of death and beyond”

Bioassociate made a presentation about the essence of bio-branding at the IATI-BioMed Conference in Tel Aviv on the 10th of June, but if you missed it, subscribe on our homepage to receive a SlideShare link and to sign up for our Elsevier Bio-Branding Webinar, coming soon!

Contact us to arrange a free Bio-Branding Consultation or to learn more!

Bioassociate has released valuation coverage on RedHill Biopharma, Ltd. (NASDAQ: RDHL) (TASE:RDHL.TA).  The Report contains a detailed discussion of RedHill’s business operations, market dynamics, macroeconomic data and indicators, financial results, potential cash flows, and risks. The valuation Report is available at: http://www.bioassociate.com/research-and-publications/publications/.

Dr. Ofir Levi , Bioassociate’s CEO: “RedHill is developing late clinical-stage, improved and patented formulations of existing drugs. RedHill’s most advanced clinical program, RHB-103 – a fast dissolving thin film formulation of rizatriptan for the treatment of migraine, submitted for FDA review by the end of Q1 2013. RedHill’s Pipeline is diverse and features six late stage clinical programs that address multi-billion dollar markets. RedHill has an experienced management team, Board of Directors and Advisory Board based in Israel, the US, Canada and Europe, with successful track record at big and small pharmaceutical companies. RedHill recently completed registration of its ADRs on the Nasdaq Global Market.  

We see great potential in RedHill’s business platform and clinical development programs. We anticipate deal making activities in the near future with RedHill’s advanced clinical programs.  For these reasons we, at Bioassociate, reached to a target price of$14.8 per share, which reflects an upside of 38% over the current share price.”

Bioassociate has initiated coverage on KaloBios Pharmaceuticals, Inc . The Initiation Report contains a detailed discussion of KaloBios’ business operations, market dynamics, macroeconomic data and indicators, financial results, potential cash flows, and risks.
The Initiation Report is available at: http://www.bioassociate.com/kalobios-pharmaceuticals-initiation-of-coverage

KaloBios Pharmaceuticals is a biopharmaceutical company focused on the development of monoclonal antibody (mAb) therapeutics. The company utilizes its proprietary Humaneered™ antibody technology platform to convert sub-optimal non-human antibodies into engineered, high-affinity human antibodies.

KaloBios currently advances three early-mid stage clinical stage programs with three different mAbs. In addition, one of the company’s leading clinical programs is licensed to Sanofi Pasteur.

KaloBios recently completed an initial public offering is now trading on the Nasdaq Global Market.

Following up from Bioassociate’s latest white paper, “2012: The Winners and Losers of the Pharmaceutical Industry”, which covered the most significant U.S. Food and Drug Administration (FDA) successes and failures of 2012, we present you with the upcoming notable events on the FDA calendar in the first quarter of 2013.

Whether it be for an avid investor or for an occasional follower of the pharmaceutical industry, significant FDA events pose some of the greatest interest, and act as some of the most explosive catalysts of change in a company’s share price. For a small biotech located anywhere in the world, a marketing approval granted by the FDA is arguably the most contested prize in the industry.

Click here to check out our latest report!

Bioassociate has unveiled a brand new office in France’s bio-hub Nice, headed by the serial entrepreneur Dr. Ari Massoudi, and will shortly be expanding into even more countries!

Air is a former entrepreneur in the medical education sector and molecular cell biology researcher in the field of stem cells, cell-therapy and regenerative medicine. Check out Adi’s bio here http://www.bioassociate.com/meet-the-team/our-team

Bioassociate just published a new summary paper on the Pharma Industry in 2012.

This report presents the biggest winners and losers of the pharma industry in 2012, from both the financial and the scientific aspects.

The financial performance of the biotechnology and healthcare indexes showed robust yield compared to the leading indexes, with the Nasdaq Biotechnology index returning ~35% growth YTD (more than 4 times that of the Dow Jones). For some of the publicly traded companies in the sector 2012 was an eventful year, with major achievements that were strongly reflected in their stock performance. The average return on investment this year for the top five companies was more than 350%, fueling up investors’ dreams.

This year we witnessed a bigger appetite for institutional funding when twelve new pharmaceutical companies entered the stock exchanges compared to the ten IPOs in 2011. The IPOs of 2012 were larger than last year, with Puma Biotechnology leading the pack with its mega IPO of $138M.

Download the report here!

Bioassociate has published an article on PharmaPhorum about the fact that bulky in-house R&D is quickly becoming a thing of the past. With better outsourcing capabilities, conglomerates are “hollowing out”, whilst new entrants are beginning to operate on fully-outsourced business models.

There are now many companies operating on a model based on outsourcing of 50%+ of their pipeline.

Click here to read the original article on PharmaPhorum!

China: what has perhaps become one of the most persistent words in everyday lives across the globe. Aside from being colossal in size, powerful and significantly richer than most countries today, China is also on the brink of monumental change, more than ever threatening to reshape the world’s economy. Having gained immense momentum from being the manufacturing hub of the world, China has now reached the natural growth limitations of its imitative economy, and is on the brink of a transition towards becoming a global innovator. The government has set sights on the pharmaceutical industry as the leader of this transformation: the latest set of China’s five year plans is so elaborately focused on revamping and innovating the domestic pharma industry, that it has been named as one of the greatest government R&D initiatives of all time.

Check out Bioassociate’s latest report to find out about all the changes currently taking place in China’s Innovative Pharma Market!